Cheers Oslo, BRIAN70,
I agree that scale up is critical and certain to be an absolute deal breaker for any company wanting to incorporate M&G, they have to have complete confidence that using M&G won't effect stability or any other aspect of the test negatively - although it does sound like incorporating it into existing systems is relatively straightforward. Perhaps Biotech can offer more detail on the practicalities, risks and advantages of large volume M&G use?
bill gates foundation press release , page-11
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
-0.002(8.33%) |
Mkt cap ! $54.31M | |||
| Open | High | Low | Value | Volume |
| 2.4¢ | 2.4¢ | 2.2¢ | $12.59K | 542.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 487271 | 2.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.3¢ | 200000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| ADO (ASX) Chart |